Medscape | ASH 2013: Big Year for CLL, Lymphoma Medscape The long-term follow-up of the PRIMA trial, which was R-chemotherapy followed by 2 years of rituximab maintenance or observation, showed a progression-free survival advantage but not an overall survival advantage. Now we are going to see what ... |
